Rhadboid tumours: HSNF/INI1 deficient cancers of early childhood with aggressive behaviour;Les tumeurs rhabdoïdes: Des tumeurs hSNF5/INI1-déficientes précoces et agressives

Bulletin du Cancer

Volumn 97, Issue 1, 2010, Pages 37-45

  Bourdeaut, F ^a,b,c   Dufour, C ^d   Delattre, O ^b,c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

ATRT; Children; hSNF5 INI1; Rhabdoid; SMARCB1

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR SNF; TRANSCRIPTION FACTOR SNF 5; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

AGGRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; GENE MUTATION; GENE REPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; PROGNOSIS; PROTEIN DEFICIENCY; REVIEW; RHABDOID TUMOR; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 22; DIFFERENTIAL DIAGNOSIS; GENE SILENCING; GENETICS; INFANT; LIVER TUMOR; METABOLISM; MUTATION; NEPHROBLASTOMA; SOFT TISSUE TUMOR; TUMOR SUPPRESSOR GENE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOMES, HUMAN, PAIR 22; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; INFANT; KIDNEY NEOPLASMS; LIVER NEOPLASMS; NEOPLASM PROTEINS; RHABDOID TUMOR; SOFT TISSUE NEOPLASMS; TRANSCRIPTION FACTORS; WILMS TUMOR;

EID: 75749146305     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.1024     Document Type: Article

References (81)

1. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 1978 ; 41 : 1937-48.
2. Tsuneyoshi M, Daimaru Y, Hashimoto H, Enjoji M. The existence of rhabdoid cells in specified soft tissue sarcomas. Histopathological, ultrastructural and immunohistochemical evidence. Virchows Arch A Pathol Anat Histopathol 1987 ; 411 : 509-14.
3. Rorke LB, Packer R, Biegel J. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol 1995 ; 24 : 21-8.
4. Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998 ; 394 : 203-6.
5. Fanburg-Smith JC, Hengge M, Hengge UR, Smith Jr. JS, Miettinen M. Extrarenal rhabdoid tumors of soft tissue: a clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol 1998 ; 2 : 351-62.
6. Kodet R, Newton Jr. WA, Sachs N, Hamoudi AB, Raney RB, Asmar L, et al. Rhabdoid tumors of soft tissues: a clinicopathologic study of 26 cases enrolled on the Intergroup Rhabdomyosarcoma Study. Hum Pathol 1991 ; 22 : 674-84.
7. Oka H, Scheithauer BW. Clinicopathological characteristics of atypical teratoid/rhabdoid tumor. Neurol Med Chir (Tokyo) 1999 ; 39 : 510-7 (discussion 7-8).
8. Morgenstern DA, Gibson S, Brown T, Sebire NJ, Anderson J. Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer 2010 ; 54 : 29-34.
9. Oda Y, Tsuneyoshi M. Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 2006 ; 56 : 287-95.
10. Birks DK, Kleinschmidt-Demasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol 2009.
11. Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004 ; 28 : 644-50.
12. Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extrarenal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 2004 ; 28 : 1485-91.
13. Bourdeaut F, Freneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Couturier J, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 2007 ; 211 : 323-30.
14. Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, et al. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 2006 ; 30 : 1462-8.
15. Perry A, Fuller CE, Judkins AR, Dehner LP, Biegel JA. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol 2005 ; 18 : 951-8.
16. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009 ; 33 : 542-50.
17. Cheng JX, Tretiakova M, Gong C, Mandal S, Krausz T, Taxy JB. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 2008 ; 21 : 647-52.
18. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Oshiro Y, Izumi T, et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol 2008 ; 32 : 1168-74.
19. Gleason BC, Fletcher CD. Myoepithelial carcinoma of soft tissue in children: an aggressive neoplasm analyzed in a series of 29 cases. Am J Surg Pathol 2007 ; 31 : 1813-24.
20. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999 ; 59 : 74-9.
21. Sévenet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999 ; 8 : 2359-68.
22. Rosty C, Peter M, Zucman J, Validire P, Delattre O, Aurias A. Cytogenetic and molecular analysis of a t(1;22)(p36;q11.2) in a rhabdoid tumor with a putative homozygous deletion of chromosome
23. Genes Chromosomes Cancer 1998 ; 21 : 82-9.
24. Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L, et al. Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 2009 ; 15 : 1923-30.
25. Roberts CW, Orkin SH. The SWI-SNF complex-chromatin and cancer. Nat Rev Cancer 2004 ; 4 : 133-42.
26. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI-SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 2008 ; 28 : 3457-64.
27. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 2002 ; 21 : 5193-203.
28. Versteege I, Medjkane S, Rouillard D, Delattre O. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene 2002 ; 21 : 6403-12.
29. Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 2002 ; 22 : 5975-88.
30. Alarcon-Vargas D, Zhang Z, Agarwal B, Challagulla K, Mani S, Kalpana GV. Targeting cyclin D1, a downstream effector of INI1/ hSNF5, in rhabdoid tumors. Oncogene 2006 ; 25 : 722-34.
31. Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV. Genetic ablation of cyclin D1 abrogates genesis of rhabdoid tumors resulting from INI1 loss. Proc Natl Acad Sci U S A 2005 ; 102 : 12129-34.
32. Caramel J, Quignon F, Delattre O. RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1. Cancer Res 2008 ; 68 : 6154-61.
33. Medjkane S, Novikov E, Versteege I, Delattre O. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization. Cancer Res 2004 ; 64 : 3406-13.
34. Caramel J, Medjkane S, Quignon F, Delattre O. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Oncogene 2008 ; 27 : 2035-44.
35. Albanese P, Belin MF, Delattre O. The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. Eur J Cancer 2006 ; 42 : 2326-34.
36. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 2000 ; 1 : 500-6.
37. Klochendler-Yeivin A, Picarsky E, Yaniv M. Increased DNA damage sensitivity and apoptosis in cells lacking the SNF5/INI1 subunit of the SWI-SNF chromatin remodeling complex. Mol Cell Biol 2006 ; 26 : 2661-74.
38. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haplo-insufficiency of SNF5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci U S A 2000 ; 97 : 13796-800.
39. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2002 ; 2 : 415-25.
40. Guidi CJ, Mudhasani R, Hoover K, Koff A, Leav I, Imbalzano AN, et al. Functional interaction of the retinoblastoma and INI1/ SNF5 tumor suppressors in cell growth and pituitary tumorigenesis. Cancer Res 2006 ; 66 : 8076-82.
41. Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, et al. Inactivation of the SNF5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A 2005 ; 102 : 17745-50.
42. Reinhard H, Reinert J, Beier R, Furtwängler R, Alkasser M, Rutkowski S, et al. Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. Oncol Rep 2008 ; 19 : 819-23.
43. Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004 ; 22 : 2877-84.
44. Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 2005 ; 23 : 7641-5.
45. Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999 ; 65 : 1342-8.
46. Janson K, Nedzi LA, David O, Schorin M, Walsh JW, Bhattacharjee M, et al. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 2006 ; 47 : 279-84.
47. Taylor MD, Gokgoz N, Andrulis IL, Mainprize TG, Drake JM, Rutka JT. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet 2000 ; 66 : 1403-6.
48. Ammerlaan AC, Ararou A, Houben MP, Baas F, Tijssen CC, Teepen JL, et al. Long-term survival and transmission of INI1-mutation via non-penetrant males in a family with rhabdoid tumour predisposition syndrome. Br J Cancer 2008 ; 98 : 474-9.
49. Jackson EM, Shaikh TH, Gururangan S, Jones MC, Malkin D, Nikkel SM, et al. High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Hum Genet 2007 ; 122 : 117-27.
50. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007 ; 80 : 805-10.
51. Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 2008 ; 45 : 332-9.
52. Swensen JJ, Keyser J, Coffin CM, Biegel JA, Viskochil DH, Williams MS. Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1. J Med Genet 2009 ; 46 : 68-72.
53. Ammerlaan AC, Houben MP, Tijssen CC, Wesseling P, Hulsebos TJ. Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation. Childs Nerv Syst 2008 ; 24 : 855-7.
54. Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, et al. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics. 2009.
55. FrühwaldMC, HasselblattM,Wirth S, Köhler G, SchneppenheimR, Subero JI, et al. Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatr Blood Cancer 2006 ; 47 : 273-8.
56. Pastore G, Znaor A, Spreafico F, Graf N, Pritchard-Jones K, Steliarova-Foucher E. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System Project. Eur J Cancer 2006 ; 42 : 2103-14.
57. van den Heuvel-Eibrink MM, Grundy P, Graf N, Pritchard-Jones K, Bergeron C, Patte C, et al. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: a collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms Tumor Study Groups. Pediatr Blood Cancer 2008 ; 50 : 1130-4.
58. Amar AM, Tomlinson G, Green DM, Breslow NE, de Alarcon PA. Clinical presentation of rhabdoid tumors of the kidney. J Pediatr Hematol Oncol 2001 ; 23 : 105-8.
59. Han TI, Kim MJ, Yoon HK, Chung JY, Choeh K. Rhabdoid tumour of the kidney: imaging findings. Pediatr Radiol 2001 ; 31 : 233-7.
60. Rosson GB, Vincent TS, Oswald BW, Wright CF. Drug resistance in malignant rhabdoid tumor cell lines. Cancer Chemother Pharmacol 2002 ; 49 : 142-8.
61. Yamamoto M, Suzuki N, Hatakeyama N, Mizue N, Hori T, Kuroiwa Y, et al. Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report. J Pediatr Hematol Oncol 2006 ; 28 : 286-9.
62. Wagner L, Hill DA, Fuller C, Pedrosa M, Bhakta M, Perry A, et al. Treatment of metastatic rhabdoid tumor of the kidney. J Pediatr Hematol Oncol 2002 ; 24 : 385-8.
63. Jayaram A, Finegold MJ, Parham DM, Jasty R. Successful management of rhabdoid tumor of the liver. J Pediatr Hematol Oncol 2007 ; 29 : 406-8.
64. Koga Y, Matsuzaki A, Suminoe A, Hatano M, Saito Y, Kinoshita Y, et al. Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney. Pediatr Blood Cancer 2009 ; 52 : 888-90.
65. Bourdeaut F, Freneaux P, Thuille B, Bergeron C, Laurence V, Brugières L, et al. Extrarenal non-cerebral rhabdoid tumours. Pediatr Blood Cancer 2008 ; 51 : 363-8.
66. Madigan CE, Armenian SH, Malogolowkin MH, Mascarenhas L. Extracranial malignant rhabdoid tumors in childhood: the Childrens Hospital Los Angeles experience. Cancer 2007 ; 110 : 2061-6.
67. Sotelo-Avila C, Gonzalez-Crussi F, deMello D, Vogler C, Gooch 3rd WM, Gale G, et al. Renal and extrarenal rhabdoid tumors in children: a clinicopathologic study of 14 patients. Semin Diagn Pathol 1986 ; 3 : 151-63.
68. Ravindra KV, Cullinane C, Lewis IJ, Squire BR, Stringer MD. Long-term survival after spontaneous rupture of a malignant rhabdoid tumor of the liver. J Pediatr Surg 2002 ; 37 : 1488-90.
69. Wagner LM, Garrett JK, Ballard ET, Hill DA, Perry A, Biegel JA, et al. Malignant rhabdoid tumor mimicking hepatoblastoma: a case report and literature review. Pediatr Dev Pathol 2007 ; 10 : 409-15.
70. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009 ; 52 : 328-34.
71. Yuri T, Danbara N, Shikata N, Fujimoto S, Nakano T, Sakaida N, et al. Malignant rhabdoid tumor of the liver: case report and literature review. Pathol Int 2004 ; 54 : 623-9.
72. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996 ; 85 : 56-65.
73. Packer RJ, Biegel JA, Blaney S, Finlay J, Geyer JR, Heideman R, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 2002 ; 24 : 337-42.
74. Lee IH, Yoo SY, Kim JH, Eo H, Kim OH, Kim IO, et al. Atypical teratoid/rhabdoid tumors of the central nervous system: imaging and clinical findings in 16 children. Clin Radiol 2009 ; 64 : 256-64.
75. Meyers SP, Khademian ZP, Biegel JA, Chuang SH, Korones DN, Zimmerman RA. Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes. AJNR Am J Neuroradiol 2006 ; 27 : 962-71.
76. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005 ; 23 : 1491-9.
77. Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group Study. Am J Surg Pathol 1998 ; 22 : 1083-92.
78. Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 2008 ; 14 : 523-32.
79. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Frühwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007 ; 120 : 1787-94.
80. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 ; 50 : 1198-206.
81. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, et al. Initial testing (stage I) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 ; 51 : 42-8.